Press N - Search Results

1

Adverse effects of antiretroviral therapy for HIV infection.

Montessori V, Press N, Harris M, Akagi L, Montaner JS. Montessori V, et al. Among authors: press n. CMAJ. 2004 Jan 20;170(2):229-38. CMAJ. 2004. PMID: 14734438 Free PMC article. Review.

2

Resolution of diabetes after initiation of antiretroviral therapy in two human immunodeficiency virus-infected patients.

Press NM, Montaner JS, Bondy G. Press NM, et al. Endocr Pract. 2004 May-Jun;10(3):199-202. doi: 10.4158/EP.10.3.199. Endocr Pract. 2004. PMID: 15310537

3

Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.

Bedell R, Heath KV, Hogg RS, Wood E, Press N, Yip B, O'Shaughnessy MV, Montaner JS. Bedell R, et al. Among authors: press n. Antivir Ther. 2003 Oct;8(5):379-84. Antivir Ther. 2003. PMID: 14640384

4

Respiratory failure associated with the lipodystrophy syndrome in an HIV-positive patient with compromised lung function.

Press N, Montessori V, Bai TR, Montaner J. Press N, et al. Can Respir J. 2001 Jul-Aug;8(4):279-82. doi: 10.1155/2001/454835. Can Respir J. 2001. PMID: 11521144 Free article.

5

Virologic and immunologic response, clinical progression, and highly active antiretroviral therapy adherence.

Press N, Tyndall MW, Wood E, Hogg RS, Montaner JS. Press N, et al. J Acquir Immune Defic Syndr. 2002 Dec 15;31 Suppl 3:S112-7. doi: 10.1097/00126334-200212153-00005. J Acquir Immune Defic Syndr. 2002. PMID: 12562032 Review.

6

HAART slows progression to anal cancer in HIV-infected MSM.

Duncan KC, Chan KJ, Chiu CG, Montaner JS, Coldman AJ, Cescon A, Au-Yeung CG, Wiseman SM, Hogg RS, Press NM. Duncan KC, et al. AIDS. 2015 Jan 28;29(3):305-11. doi: 10.1097/QAD.0000000000000537. AIDS. 2015. PMID: 25686679

7

Case series assessing the safety of mycophenolate as part of multidrug rescue treatment regimens.

Press N, Kimel G, Harris M, Yip B, Craib KJ, Montaner JS. Press N, et al. HIV Clin Trials. 2002 Jan-Feb;3(1):17-20. doi: 10.1310/B6T0-N98J-1J3M-EQPK. HIV Clin Trials. 2002. PMID: 11819181 Clinical Trial.

8

Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up.

Hogg RS, Heath K, Bangsberg D, Yip B, Press N, O'Shaughnessy MV, Montaner JS. Hogg RS, et al. Among authors: press n. AIDS. 2002 May 3;16(7):1051-8. doi: 10.1097/00002030-200205030-00012. AIDS. 2002. PMID: 11953472

9

Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy.

Palepu A, Tyndall MW, Joy R, Kerr T, Wood E, Press N, Hogg RS, Montaner JS. Palepu A, et al. Among authors: press n. Drug Alcohol Depend. 2006 Sep 15;84(2):188-94. doi: 10.1016/j.drugalcdep.2006.02.003. Epub 2006 Mar 20. Drug Alcohol Depend. 2006. PMID: 16542797

10

Mortality among people living with HIV/AIDS with non-small-cell lung cancer in the modern HAART Era.

Smith DM, Salters KA, Eyawo O, Franco-Villalobos C, Jabbari S, Wiseman SM, Press N, Montaner JSG, Man SFP, Hull M, Hogg RS. Smith DM, et al. Among authors: press n. AIDS Care. 2018 Jul;30(7):936-942. doi: 10.1080/09540121.2018.1434120. Epub 2018 Feb 7. AIDS Care. 2018. PMID: 29411625

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

135 results

Search Page